Biofil Chemicals & Pharmaceuticals Share Price

Biofil Chemicals & Pharmaceuticals Investment Rating

• Master Rating:

• Biofil Chemicals & Pharmaceuticals has an operating revenue of Rs. 29.32 Cr. on a trailing 12-month basis. An annual revenue de-growth of -38% needs improvement, Pre-tax margin of 5% is okay, ROE of 4% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 51 which is a POOR score indicating inconsistency in earnings, a RS Rating of 14 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 151 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.